Is PULM or PYXS more undervalued in 2026?

CirclFi compares Pulmatrix, Inc. (PULM) and Pyxis Oncology, Inc. (PYXS) using 13 institutional-grade valuation models. PULM has a Quality of Company score of 5.6/10 while PYXS scores 5.1/10.

Which is a better buy — PULM or PYXS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do PULM and PYXS valuations compare?

PULM at $1.39 and PYXS at $1.80 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

PULM vs PYXS Valuation Comparison 2026 — Intrinsic Value Analysis

PULM

Pharmaceutical Preparations

Pulmatrix, Inc.

Quality

5.6

out of 10

Value Trap

SAFE

Price

$1.39

Last close

Models

9/13

Active

PYXS

Pharmaceutical Preparations

Pyxis Oncology, Inc.

Quality

5.1

out of 10

Value Trap

SAFE

Price

$1.80

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	PULM Fair Value	PULM Upside	PYXS Fair Value	PYXS Upside
Bayesian DCF	Intrinsic	$0.84	-39.7%	$0.48	-73.1%
Earnings Power Value	Intrinsic	—	—	$1.12	-34.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$3.25	+133.5%	$1.44	-19.9%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for PULM vs PYXS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

PULM vs PYXS — Which Stock Is More Undervalued?

PULM scores higher with a 5.6/10 quality rating vs PYXS's 5.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Pulmatrix, Inc. (PULM) and Pyxis Oncology, Inc. (PYXS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

PULM currently trades at $1.39 with a QOC of 5.6/10, while PYXS trades at $1.80 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).